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Gender effects of single nucleotide 
polymorphisms and miRNAs 
targeting clock-genes in metastatic 
colorectal cancer patients (mCRC)
Carlo Garufi1,*, Elisa Giacomini2, Angela Torsello3, Isabella Sperduti4, Elisa Melucci5, 
Marcella Mottolese5, Massimo Zeuli6, Giuseppe Maria Ettorre7, Teresa Ricciardi2, 
Francesco Cognetti6, Mauro Magnani2 & Annamaria Ruzzo2,*
The circadian system is composed of a set of clock-genes including PERIOD, CLOCK, BMAL1 and 
CRY. Disrupting this system promotes cancer development and progression. The expression levels 
of miR-206, miR-219, miR-192, miR-194 and miR-132 regulating clock-genes and three functional 
polymorphisms rs11133373 C/G, rs1801260 T/C, rs11133391 T/C in CLOCK sequence were associated 
with the survival of 83 mCRC patients (50 males and 33 females). Longer overall survival (OS) was 
observed in women compared to men, 50 versus 31 months. This difference was associated with 
rs11133373 C/C genotype (p = 0.01), rs1801260 T/C+C/C genotype (p = 0.06) and rs11133391 T/T 
genotype (p = 0.06). Moreover women expressing high levels (H) of miR-192 (p = 0.03), miR-206 
(p = 0.003), miR-194 (p = 0.02) and miR-219 (p = 0.002) had a longer OS compared to men. In women 
longer OS was reinforced by the simultaneous presence of two or more H-miR, 58 months versus 15 
months (p = 0.0008); in this group of women an OS of 87 months was reached with the additional 
presence of rs11133391T/T genotype (p = 0.02). In this study we identified a subgroup of female 
patients who seems to have a better prognosis. Personalized medicine should prospectively take into 
account both genetic and gender differences.
The circadian system is a coordinated network of biological clocks that drive 24 h changes in metabolism and 
proliferation with the suprachiasmatic nucleus (SCN) of the hypothalamus synchronizing circadian oscil-
lations in most peripheral tissues, including the gastrointestinal tract. A molecular clock, based on circadian 
variation in a set of clock-genes, has been validated at a cellular level where two transcriptional factors Clock 
and Bmal1 (CLOCK and BMAL1 gene) activate their targets, Per (PERIOD1, 2 and 3 gene) and Cry (CRY1 and 
2 gene)1,2. The Clock plays a central role in regulating the circadian rhythm. It is a transcription factor of the 
basic helix-loop-helix (bHLH) which contains DNA binding histone acetyltransferase activity. The clock forms a 
heterodimer with Bmal1 that binds E-box enhancer elements upstream of PERIOD and CRY and activates tran-
scription of these genes. Subsequently Cry and Per interfere with Clock/Bmal1 activity repressing their own tran-
scription by interacting in a negative feedback loop. Experimental data show that the disruption of the circadian 
rhythm is responsible for several metabolic-related diseases where increasing evidence has raised the possibility 
that the circadian rhythm genes may play an important role in human cancer development and progression1.
Large population-based studies have documented a relatively high degree of polymorphisms in the human 
CLOCK and have shown how several of them affect the subject’s phenotype3–7. Previous genetic association stud-
ies have proven that there are three functional single nucleotide polymorphisms in the CLOCK sequence linked to 
cancer and phenotype, these include: rs11133373 C/G and rs11133391 T/C, linked to prostate and breast cancer, 
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and rs1801260 T/C, linked to several phenotypes, such as sleep disturbance, mood weight loss bipolar disorders, 
breast and CRC2,4,6–9. Karantanos et al.7, in a case-control study in 402 patients and 480 healthy controls showed 
that the 311T> C CLOCK gene polymorphism was associated with an increased risk of colorectal cancer devel-
opment but with no difference in outcome. Alexander et al.6 confirmed an increased risk for adenoma in another 
case-control study when the PERIOD3 gene length polymorphism was evaluated.
Clock-genes are regulated by different miRNAs and among these miR-192, miR-194, miR-206, miR-132 
and miR-219 are associated with different types of cancer such as breast, lung and gastrointestinal cancer10–16. 
MiRNAs are small non coding RNA molecules that regulate gene expression by binding partially to complemen-
tary target sites within the 3′ -untranslated regions (3′ -UTRs) of select mRNAs. MiRNAs act as potent negative 
regulators of protein translation either by directing the mRNA for degradation or inhibiting its translation into 
the encoded protein. This level of regulation can affect virtually all aspects of the circadian system, from the core 
timing mechanism and input pathways that synchronize clocks to the environment and output pathways that 
control overt rhythmicity11.
Recently it has been reported that differences in survival are related to gender and to specific genetic 
profiling17,18.
In this study, for the first time, three functional polymorphisms in the CLOCK sequence, and five miRNAs 
regulating CLOCK, BMAL1 and PERIOD in advanced colorectal cancer patients and their effect on survival were 
analyzed.
Results
Patients data. Patient data are shown in Table 1. Most of the patients (78%) received first line triplet chemo-
therapy (fluorouracil plus oxaliplatin and irinotecan) ± monoclonal antibody, 82% were KRAS wild-type and 55% 
of them were resected for liver metastases after induction chemotherapy. Median progression free survival (PFS) 
was 14 months and median overall survival (OS) was 35 months. Women were observed to have better median 
PFS and OS than men, 19 months versus 12 months (2 years-PFS 25.8% vs 12.3%, p = 0.03) and 50 months versus 
31 months (3 years-OS 61.5% vs 35.9%, p = 0.03), respectively (Fig. 1 and Table 1). Differences in prognostic 
factors between the female and male groups were also observed for age and chronomodulated therapy (p = 0.04), 
as reported in Table 1.
Polymorphisms. Seventy six of the 83 the patients were genotyped for rs11133373 C/G, rs1801260 T/C and 
rs11133391 T/C polymorphisms. The genomic DNA of 7 cases was either consumed or degraded. No departures 
No
%
Male
%
Female
% p-value***83 50 33
Median Age (years-range) 59 (30–85) — 59 (44–85) — 57 (30–73) — 0.21
< = 59/59> 16/67 19/81 6/44 12/88 10/23 30/70 0.04
Performance Status: 0 vs 1/2 65/18 78/22 38/12 76/24 27/6 82/18 0.53
Menopause No/Yes — — — — 10/23 30/70 —
Primary tumor resected: Yes/No 76/7 92/8 44/6 88/12 32/1 97/3 0.23
Site metastases: liver/other sites 48/35 58/42 30/20 60/40 18/15 55/45 0.62
Metastases: synchronous/metachronous 75/8 90/10 43/7 86/14 32/1 97/3 0.14
Resection of liver metastases: Yes/No 36/47 43/56 18/32 36/64 18/15 55/45 0.10
KRAS mutated: No/Yes 68/15 82/18 42/8 84/16 26/7 80/21 0.55
BRAF mutated: No/Yes 63/2 99/3 36/1 97/3 27/1 96/4 0.99
BRAF missing 18 22 13 26 5 15 0.29
First line Therapy
 Triplet* combination 39 48 24 48 15 46
0.12
 Triplet* + cetuximab 25 30 11 22 14 42
 Douplet** + cetuximab 12 15 9 18 3 9
 Douplet** ± bevacizumab 5 7 6 12 1 3
 Chronomodulated infusion: Yes/No 57/26 69/31 30/20 60/40 27/6 82/18 0.04
Response to first line therapy
 Complete response 2 2 2 4 0 0
0.64
 Partial response 55 66 31 62 24 73
 Stable disease 16 19 10 20 6 18
 Progressive disease 8 10 6 12 2 6
 Not assessable 2 2 1 2 1 3
 Median follow-up (months) 25 (range 1–132) — 20 (range 1–121) — 41 (range 3–132) — 0.05
 Median OS (months) 35 (CI 95% 21.5–47.5) — 31 (CI 95% 22.0–39.1) — 50 (CI 95% 35.0–64.0) — 0.03
 Median PFS (months) 14 (CI 95% 10–18.9) — 12 (CI 95% 7.6–15.5) — 19 (CI 95% 10.7–26.8) — 0.03
Table 1.  Patient data. Triplets*: 5-fluorouracil, folinic acid, oxaliplatin or irinotecan. Douplets**: 5-fluorouracil, 
folinic acid + oxaliplatin or irinotecan. Log-rank test***.
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from Hardy-Weinberg equilibrium were observed and the frequencies did not show any differences when com-
pared to the Italian population (TSI, Tuscany) (data not shown). No associations were observed in the entire 
population between polymorphisms and patient and tumour characteristics nor with clinical outcome, PFS and 
OS. Only performance status was linked to rs11133391 T/T genotype with a relative risk of 1.2 (95% CI 1–1.5; 
p = 0.04).
rs11133373 C/G. When analysed by gender, results showed a better survival rate in women compared to 
men with rs11133373 C/C, median PFS of 23 months vs 11 months (2 years-PFS 33.3% vs 6.3%, p = 0.006) and 
median OS of 57 months vs 18 months (3 years-OS 70.1% vs 25.0%, p = 0.01), respectively (Fig. 2A). In women 
the C/C genotype was also associated with a longer PFS and OS compared to C/G+ G/G genotype (23 months vs 
16 months and 57 months vs 44 months, respectively) while the opposite effect happened in men (11 months vs 
14 months and 18 months vs 32 months, respectively) (supplementary Table S1).
rs1801260 T/C. Results showed a better survival rate in women compared to men with rs1801260 T/C+ C/C 
genotype, median PFS of 20 months vs 11 months (2 years-PFS 17.6% vs 7.1%, p = 0.03) and median OS of 50 
months vs 17 months (3 years-OS 50.7 vs 16.5%, p = 0.06), respectively (Fig. 2B).
rs1133391 T/C. The rs11133391 T/T genotype was associated with longer median PFS of 23 months vs 10 
months (2 years-PFS 33.3% vs 12.4%, p = 0.04) and median OS of 87 months vs 25 months (3 years-OS 70.1 vs 
25.4% p = 0.06), respectively (Fig. 2C). We also found that the T/T genotype was associated with a longer OS 
compared to T/C+ C/C genotype (87 months vs 44 months) (see supplementary Table S1). We did not find any 
differences between performance status and T/T genotype in patients divided by gender.
miRNA expression levels. The expression levels of miR-192, miR-206, miR-194, miR-219 and miR-132 
were successfully performed in 81 cases (49 males and 32 females). The expression levels of each miRNA were 
separated into High (H) and Low (L) categories and the association analysis between H and L of each miRNA and 
survival of patients were analyzed. No significant associations were found between miRNAs and patient data with 
the exception of hepatic resection: we found 12 patients with hepatic resection vs 29 without hepatic resection 
in the L-miR-194 group and 24 patients with hepatic resection vs 16 without hepatic resection in the H-miR-194 
group reaching a relative risk of 1.77 (95% CI 1.15–2.71; p = 0.009).
miRNAs expression levels and gender effect. When patients were divided by sex, women expressing 
H-miR-192, H-miR-206, H-miR-194 and H-miR-219 had a longer survival compared to men.
miR-192. Women with H-miR-192 showed a median PFS of 16 months vs 12 months in men (2 years-PFS 
28.6% vs 5.4%, p = 0.09) and a median OS of 51 months vs 31 months (3 years-OS 61.5% vs 28.7%, p = 0.03), 
respectively (Fig. 3A).
miR-206. Women with H-miR-206 showed a median PFS of 20 months vs 10 months in men (2 years-PFS 
33.3% vs 11.6%, p = 0.006) and median OS of 56 months vs 20 months (3 years-OS 75.6% vs 22.6%, p = 0.003), 
respectively (Fig. 3B). Women with H-miR-206 had a longer survival compared to those with L-miR-206 with 
an 11 month difference for PFS and 25 months for OS. In contrast men with H-miR-206 had a shorter survival 
compared to those with L-miR-206 with a 4 month difference for PFS and 12 months for OS (supplementary 
Table S2).
miR-194. Women with H-miR-194 showed a median PFS of 19 months vs 12 months in men (2 years-PFS 
25.0% vs 0.0%, p = 0.01) and median OS of 56 months vs 32 months (3 years-OS 67.0% vs 32.4%, p = 0.02), 
respectively (Fig. 3C).
Figure 1. Kaplan-Meier plot of Progression Free Survival (PFS) at 2 years and Overall Survival (OS) at 3 
years of patients according to sex. 
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miR-219. Women with H-miR-219 showed a median PFS of 20 months vs 11 months (2 years-PFS 30.8% vs 
6.5%, p = 0.02) and median OS of 58 months vs 25 months (3 years-OS 75.0% vs 26.4%, p = 0.002), respectively 
(Fig. 3D). Women with H-miR-219 had a longer survival compared to those with L-miR-219 with a 4 month dif-
ference for PFS and 8 months for OS. On the contrary men with H-miR-219 had a shorter survival compared to 
those with L-miR-219 with an 8 month difference for PFS and 6 months for OS (supplementary Table S2).
miR-132. Women with L-miR-132 had a longer PFS and OS compared to those expressing H-miR-132 with a 
difference of 5 months and 13 months, respectively (supplementary Table S2).
Subsequently, an additional analysis was performed in women expressing two or more H-miR simultaneously 
versus none and we found that the first group had a median OS of 58 months versus 15 months (3 years-OS 68.9% vs 
25.0%, p = 0.0008). This effect was further increased by the presence of rs11133391T/T genotype (2 years-OS 73.3% 
vs 50.7%, p = 0.02) with a median OS of 87 months vs 44 months, as shown in Fig. 4 (supplementary Table S3).
Figure 2. Kaplan-Meier plot of Progression Free Survival (PFS) at 2 years and Overall Survival (OS) at 3 
years in Female versus Male with rs11133373 C/C genotype (A), rs1801260 T/C+ C/C genotype (B) and 
rs11133391 T/T genotype (C). 
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Discussion
This study highlights that functional rs11133373 C/G, rs1801260 T/C, rs11133391 T/C CLOCK polymorphisms 
as well as expression levels of miR-192, miR-206, miR-194 and miR-219 related to clock-genes, are differently 
associated with survival in women and men with mCRC, suggesting that the circadian system plays a role in 
this gender-effect result. Moreover this study indicates that these genetic variants could be used as sex-specific 
prognostic biomarkers because an opposite expression effect in women and in men related to survival was found.
Treatment of advanced colorectal cancer has profoundly evolved over the last twenty years from mono chemo-
therapy with 5-fluorouracil modulated by folinic acid to double or triple combination chemotherapy plus a mon-
oclonal antibody. Moreover the selection of RAS mutation has identified a subset of patients who cannot benefit 
from anti-EGFR antibodies such as cetuximab or panitumumab. These changes, together with the use of resection 
of liver metastases, was the reason for the survival shift from 12 months to more than 30 months19,20 as in this 
series with a median PFS of 14 months and median OS of 35 months. With reference to drugs delivery in cancer 
patients according to circadian rhythms, three trials compared conventional versus time-dependent adminis-
tration of 5-fluorouracil-folinic acid and oxaliplatin. In the last of these trials improved survival was found in 
men treated with chronomodulated infusion and in women treated by conventional flat infusion21. When ana-
lyzed together, a meta-analysis confirmed a significant three-month median survival improvement in men versus 
women with chronoinfusion and the contrary in female patients receiving flat infusion suggesting a gender effect 
in the modulation of time-delivered treatment schedule22.
On the contrary, opposite results were found in these 83 advanced colorectal cancer patients. Most of them 
were administered a three drug combination ± cetuximab, female patients were significantly younger than men 
Figure 3. Kaplan-Meier plot of Progression Free Survival (PFS) at 2 years and Overall Survival (OS) at 3 
years in Female versus Male with H-miR-192 (A), H-miR-206 (B), H-miR-194 (C) and H-miR-219 (D). 
Figure 4. Kaplan-Meier plot of Overall Survival (OS) at 3 years, in women with ≥ 2 H-miR versus ≤ 1 H-miR 
(A) and in women with ≥ 2 H-miR + rs11133391 T/T genotype versus women without ≥ 2 H-miR + rs11133391 
T/T (B). 
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and were mostly treated by chronomodulated infusion. In this population female patients had significantly better 
median PFS (19 versus 12 months) and OS (50 versus 31 months) than men. Thus a possible explanation for rely-
ing on the different signatures in clock-genes regulation according to gender could be plausible.
Sexual dimorphism has been observed in most human diseases23–25. Both hormonal and genetic differences 
between men and women can lead to differences in gene expression patterns that can influence disease risk and 
course even in cancer. Although CRC is more frequent in men, prognosis seems to be better in women. Majek 
et al.26 showed in a German population of 164,996 patients an age-adjusted 5-year relative survival higher in 
women (64.5% vs 61.9%, p < 0.0001). This was then confirmed at the multivariate analysis in subjects under 65 
years of age with an excess attributable risk of death lower than 14%. In this group, women have fewer adenomas 
but roughly equivalent to the number of colorectal cancers found in men. Simon et al.27 reported that women 
randomized to receive estrogen/progesterone in the Women’s Health Initiative had a lower rate of CRC but a 
greater number of positive lymph nodes than women in the placebo group. Female patients treated in the adju-
vant setting benefit more than men after resection of colon cancer26–28. Gender related differences in survival were 
advocated for urothelial and kidney cancer29. Stage and gender were found to be prognostic factors for survival 
in lung cancer30. In a series of 11,774 melanoma cases a significant female advantage was observed for melanoma 
specific survival. They were at a lower risk of progression and maintained a significant survival advantage after 
first progression and lymph node metastases31.
Functional polymorphisms of EGFR are inversely related to gender specific OS in mCRC: the EGFR (CA)n 
repeat polymorphism was associated with OS in female patients, with females carrying fewer than (CA)20 
repeats having better OS and was associated to increased EGFR expression, while in males the opposite was 
observed18. Also estrogen receptor ß (Erß) polymorphisms have been shown to be relevant and gender related 
in advanced colorectal cancer32. Press et al.18 showed that female patients with less than (CA)22 repeat alleles 
had short OS compared to female patients that had in homozygous more than (CA)22 repeat alleles, while the 
opposite difference in survival was found in men. Finally a link between EGFR signaling and the circadian system 
has been shown. Lauriola et al.33 showed that in animals glucocorticoids inhibit signaling downstream of EGFR 
through a circadian control mechanism: EGFR signals are suppressed by glucocorticoids during the active phase 
(night-time in rodents) while EGFR signals are enhanced during the resting phase. It was also demonstrated that 
KRAS overexpression can disrupt the circadian clock in metastatic cell lines34. We used the miRDB data base 
(mirdb.org/miRDB) for predicting the potential of miRNA-mRNA interaction also in the EGFR pathway. We 
found that miR-192, miR-206 and miR-194 have binding sites on EGFR mRNA; miR-206, miR-132, miR-194 and 
miR-219 on KRAS mRNA; miR-192 on ESR2 (Erß) mRNA; and miR-219 on EGF mRNA. Thus our hypothesis is 
that the biological framework of colorectal cancer in women seems to be characterized by Erß signaling, EGFR 
activation and circadian clock control, all interacting mechanisms, involved in tumour growth.
This study has several limitations. It is a retrospective study with a limited number of patients, so it can only be 
used to generate a hypothesis. Whereas the main strength of the study is that all the patients were treated by the 
same clinical group and follow-up was sufficiently long. Prospective, cooperative studies are needed to explore 
the mechanisms by which CLOCK polymorphisms and miRNA expression levels related to clock-genes exert 
their effect on EGFR or on other pathways. In the era of precision medicine the goal of treating men and women 
differently with advanced colorectal cancer is a promising challenge.
Methods
Patients. The cohort of patients was retrospective and consisted of 83 patients diagnosed with mCRC treated in 
one single center. Patients were required to have a histologically confirmed diagnosis of advanced CRC and available 
Formalin-Fixed, Paraffin-Embedded tissue (FFPE) samples of the primary tumor and peripheral blood samples. All 
experiments were performed in accordance with relevant guidelines and regulations. The study was approved by the 
Ethics Commitee of the Regina Elena National Cancer Institute in Rome and signed informed consents were collected.
The primary end-point of the study was the evaluation of survival outcome according to the SNPs and miR-
NAs expression levels. Additional analyses were addressed to compare miRNAs and SNPs according to clinical 
features.
The genotype analysis of rs11133373 C/G, rs1801260 T/C and rs11133391 T/C polymorphisms was performed 
on genome DNA (gDNA) extracted from peripheral blood cells in patients. The miRNA expression level analysis 
of miR-192, miR-206, miR-132, miR-194 and miR-219 was performed on miRNAs extracted from FFPE samples.
See under “supplementary Material and Methods” the Table S4 for nucleic acids extraction (gDNA and 
miRNA) and PCR conditions, for the miRNAs expression level analysis see Figure S1(A–E).
Statistical Method. rs11133373 C/G, rs1801260 T/C and rs11133391 T/C were checked for any deviations 
from the Hardy-Weinberg equilibrium. The frequencies of each SNP in the cohort of patients were compared 
with the general Italian population (TSI, http://www.ensembl.org/info/genome/variation/index.html). According 
to the frequency of the minor allele and the low frequency of the homozygous variant genotype, we decided to 
collapse the heterozygous and minor allele homozygous in all the analyses performed. The expression levels of 
miR-192, miR-206, miR-132, miR-194 and miR-219, were expressed as values obtained from the Δ Ct equation 
of each miRNA to test with respect to RNU-6-2 used as reference gene (Δ Ct = Cttarget − Ctreference). Median Δ Ct 
values were employed for splitting miRNA expression levels into two groups, High expression level (H) and Low 
expression level (L).
The Chi-Square or Fisher Exact tests were used to estimate all associations between categorical variables. 
Quantitative variables were compared using the non-parametric Mann–Whitney test. The Odds Ratio (OR) and the 
95% confidence intervals (95% CI) were estimated for each variable using the logistic univariate regression model.
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Overall survival (OS) and Progression-free Survival (PFS) were calculated by the Kaplan-Meier product-limit 
method. PFS was calculated as the time from the start date of the first line therapy until date of progression or date 
of last follow-up evaluation. OS survival was calculated as the time from the start date of the first line therapy until 
to the date of death or last contact. Log-rank test was used to assess the differences between subgroups.
All reported P-values were based on two-sided tests, and a P-value of less than or equal to 0.05 was considered 
statistical significant.
SPSS software was used for all statistical evaluations (SPSS version 21.0, SPSS Inc., Chicago, Illinois, USA).
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